These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Hydroxyurea versus busulfan in the treatment of chronic myelogenous leukemia. Rushing D; Goldman A; Gibbs G; Howe R; Kennedy BJ Am J Clin Oncol; 1982 Jun; 5(3):307-13. PubMed ID: 6952759 [TBL] [Abstract][Full Text] [Related]
13. [Malignant phase and haematological patterns of metamorphosis on seventy cases of chronic granulocytic leukaemia (author's transl)]. Outeiriño J; Sánchez Fayos J; Calabuig T; Torres P; García Villaescusa R; Pérez Saldaña MR; Paniagua G Sangre (Barc); 1981; 26(5-A):605-9. PubMed ID: 6948411 [No Abstract] [Full Text] [Related]
14. [The use of hydroxyurea (Biosuppressin) in the accelerated phase of chronic myeloid leukemia]. Kiss A; Jakó J; Rák K Folia Haematol Int Mag Klin Morphol Blutforsch; 1981; 108(2):275-80. PubMed ID: 6168539 [No Abstract] [Full Text] [Related]
15. [Clinical effects of Vercyte(A-803) on chronic myelogenous leukemia]. Kinugasa K; Takaku F; Sasa S; Mizoguchi H; Komine M Naika; 1971; 28(1):151-6. PubMed ID: 5284419 [No Abstract] [Full Text] [Related]
16. Chronic myelogenous leukemia: a clinical and experimental evaluation of splenectomy and intensive chemotherapy. Brodsky I; Fuscaldo KE; Kahn SB; Conroy JF; Lamping CG Ser Haematol; 1975; 8(4):143-56. PubMed ID: 798283 [No Abstract] [Full Text] [Related]